# Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer

> **NCT03269344** · PHASE3 · COMPLETED · sponsor: **Henry Ford Health System** · enrollment: 65 (actual)

## Conditions studied

- Oropharynx Cancer

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT03269344
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-05
- **Primary completion:** 2020-12-09
- **Final completion:** 2020-12-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03269344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03269344, "Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03269344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*